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Surgical repair is indicated for large asymptomatic abdom-
inal aortic aneurysms (AAA) in patients with an acceptable
operative risk. Following Parodi’s landmark paper,1 early
results of randomized controlled trials (RCTs)2e4 have
demonstrated lower peri-operative mortality after endo-
vascular aortic aneurysm repair (EVAR) compared with open
surgical repair (OSR). Next to these results, the number of
patients receiving EVAR exceeded those treated by OR.5
However, some years later, the mid-term results of these
RCTs have shown equivalent mortality after either EVAR or
OSR, with a signiﬁcantly higher re-intervention rate after
EVAR, failing to support evidence favoring its use as ﬁrst-
line therapy, especially in young and/or ﬁt patients.6e8
The goal of this debate is to compare early and late out-
comes in patients younger than 65 years receiving OSR or
EVAR.THE PROBLEM
Over the last decade, EVAR has radically changed the
approach for treating AAA. In the USA EVAR rose from
11,171 procedures in 2001 to 21,725 procedures in 2006.5
The same paradigm shift was observed in France, regard-
less of patient age, with 777 EVAR procedures in 2006
compared with 372 in 2001.9 Currently, in the USA, 60% of
AAAs are repaired by EVAR.10 But the use of EVAR in young
patients calls into question the long-term beneﬁts and
durability of this procedure. To answer these questions,
analysis of the survival rate, of the risk of device-related
complications, including radiation exposure by computed
tomography (CT) scan,11 and cost-effectiveness with regard
to devices and re-interventions are essential (Table 1).THE EVIDENCE
Comparison of EVAR with OSR in patients deemed ﬁt for
surgery is available in four RCTs (Table 2). EVAR 1 involved
1,252 patients from 1999 to 2004.8 This trial demonstrated
an initial beneﬁt in terms of aneurysm-related mortality in
favour of EVAR at 6 months. But this beneﬁt vanished after
4 years, and the risk of aneurysm-related death, around 7%,
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EVAR group. At 8 years, the complication rate was 52% for
EVAR versus 15% for OSR (p ¼ .01), and the re-intervention
rate was 28% for EVAR versus 10% for OSR. In addition, 25
aortic ruptures, with 18 deaths, occurred in the EVAR group
(4%) and none in the OSR group. These late ruptures out-
weighed the initial beneﬁts of EVAR.
The DREAM trial4,7 demonstrated the same initial bene-
ﬁts for EVAR, with a lower rate of in-hospital mortality
(1.2% vs. 4.6% for OSR; p < .05), but with a higher rate of
cardiovascular-related death in the EVAR group at 1 year,
which outweighed its initial beneﬁt in terms of survival at 2
years. There were also more re-interventions in the EVAR
group (29.6% for EVAR vs. 18.1% for OSR; p ¼ .03) with an
increased rate of re-interventions after 4 years in the EVAR
group, 75% of which were related to stent graft failure.
The OVER trial2,6 also showed a signiﬁcant decrease in
hospital mortality in favour of EVAR compared with OSR
(0.5% vs. 3%, respectively; p ¼ .004), which remains sig-
niﬁcant at 3 years. In contrast to the EVAR 1 and DREAM
trials, there was no difference in the rate of re-interventions
between EVAR and OSR during this study. In this trial,
mortality was analysed according to several risk factors,
including age, and showed an advantage for EVAR in young
patients (<70 years) compared with OSR, even if a higher
incidence of cancer in the OSR group could explain this
difference and even though six AAA ruptures with three
deaths occurred in the EVAR group.
The results of the ACE (Anévrysme de l’aorte abdominale,
Chirurgie versus Endoprothèse) trial12 comparing OSR
(n ¼ 149) with EVAR (n ¼ 150) in low-to-moderate-risk
patients showed no signiﬁcant difference in in-hospital
mortality between the two groups (0.6% for OSR vs. 1.3%
for EVAR; p ¼ 1.0). However, there was a higher rate of re-
interventions in the EVAR group (16% vs. 2.7%; p < .0001),
with three ruptures resulting in two deaths versus no
rupture in the OSR group. The absence of early beneﬁt of
EVAR in this trial was explained by the low mortality rate of
the OSR group.WHAT HAVE WE LEARNED FROM THESE STUDIES?
These four RCTs did not investigate the performance of EVAR
amongst different age groups. The mean age of patients in
these RCTs did not match with the deﬁnition of young pa-
tients, and calls into question the applicability of their con-
clusions for young patients. Other studies have concentrated
exclusively on the elderly population.13,14 However, with the
development of AAA screening there will surely occur an
Table 1. Reasons for skepticism regarding endovascular aortic
aneurysm repair (EVAR) as a ﬁrst-line therapy for young patients.
1. Failure to improve survival during long-term
follow-up
2. New devices are more likely used outside
instructions for use with worse effects on durability
3. Longer life expectancy of young patients increases
the risk of endograft-related complications after
EVAR, including the risk of late abdominal aortic
aneurysm rupture
4. Need for follow up by computed tomography scan
with radiation exposure and increased cancer risk
5. EVAR is not cost-effective for patients ﬁt for surgery
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retrospective study of data extracted from the American
College of Surgeons NSQIP data ﬁles, Gupta et al.15 compared
the results of EVAR in patients aged 60 years and older versus
younger patients. This study failed to show any early beneﬁt
in terms of mortality for EVAR compared with OSR (1.1% for
EVAR vs. 0.4% for OSR; p ¼ .22). However, major complica-
tionswere signiﬁcantly higher forOR than for EVAR (18.8% vs.
9.2%, respectively; p ¼ .0004). This contemporary study
demonstrates that 30-day mortality after OSR was compa-
rable to 30-daymortality after EVAR in patients younger than
60 years.
In association with age, women have been reported to
have a higher risk for complications after AAA repair.16 In
this study involving patients younger than 60 years,
female gender was not associated with 30-day mortality or
morbidity on multivariate regression analysis. A recent
study showed that women with AAA were signiﬁcantly
older than men and less likely to undergo EVAR as a result
of a less favourable vascular anatomy.17 These data suggest
a limited impact of female gender on outcome for young
patients.TECHNICAL IMPROVEMENTS OF EVAR
The use of ﬁrst-generation stent grafts and early experience
of EVAR are signiﬁcant factors that have resulted in some
of the complications reported in EVAR 1, DREAM, and
OVER.14 Technical improvements of EVAR securing the
sealing zone more precisely and decreasing stent graft-
related complications call into question the use of these
results nowadays. Two pivotal studies with recent stent
grafts have reported a rate of device-related complications
of less than 3%, with only one rupture during follow-
up.18,19 Less promising in these studies are the 15% rate of
type II endoleak reported in the Zenith pivotal study19 and
the 15% rate of sac enlargement without visible endoleak
in 15% of patients in the Excluder Low-Permeability Pivotal
Study.20 These recent data question the efﬁcacy of stent
grafts, even with the newest-generation devices. Moreover,
a worrisome recent report by Schanzer et al.21 showed anincidence of post-EVAR aneurysmal sac enlargement of 41%
at 5 years, despite the use of new-generation stent grafts.
The main reason for this adverse outcome was partially
related to a more liberal indication of EVAR exceeding the
instructions for use. More than patient preference, appro-
priate anatomical criteria are critical in deciding between
OR and EVAR in this young population.STENT GRAFT OUTCOME IN YOUNG PATIENTS REMAINS A
CONCERN IF THEY LIVE LONG ENOUGH
The main limitation in recommending EVAR in young pa-
tients is the risk of stent graft-related complication due to
their longer life expectancy. Some authors, citing the re-
sults of the Multicentre Aneurysm Screening Study with
11% of patients dying within 4 years of their aneurysm
operation,22 consider that the life expectancy of these
young patients is already poor. The majority of them are
likely to die from coronary disease, cancer, or other car-
diovascular causes. A recent study by Darwood et al.23
reported a 42% mortality at 2 years in patients with a
4e5 cm AAA. They speculate that even though they are
young, these patients with AAA have a short life expec-
tancy and that a stent graft was all that was required.
Perhaps the main issue in these young patients with AAA
is not the choice of EVAR or OSR, but the prevention of
cardiovascular complications with better medical man-
agement, including statin therapy.
However, there is no level 1 evidence to support this
hypothesis, and long-term RCTs have shown that the dif-
ference in morbidity between OSR and EVAR in the DREAM
and in the EVAR 1 trials was partially explained by a higher
rate of re-intervention after EVAR,7,8 even when taking into
account an underestimation of the late complications
following OSR.24 These data suggest that young patients do
survive long enough to face stent graft-related complica-
tions, including AAA rupture, which remains three times
more frequent after EVAR than after OSR.24
It is also clear that prior EVAR does not confer any pro-
tective effect in the setting of a ruptured AAA.25 The risk of
ruptured aneurysm after EVAR underscores the need for
regular monitoring by CT scan with the risk of radiation
exposure during many years of follow-up. A CT scan with
contrast media at 1, 6, and 12 months, and annually
thereafter, is tantamount to a total effective radiation dose
of 145e205 mSv over 5 years, which translates into a life-
time cancer risk of 1% for a 50-year-old patient.11 To limit
radiation exposure, some authors recommend a “light”
follow-up based on the results of an early CT scan.26 The
most promising solution consists of the use of contrast-
enhanced ultrasound, which has demonstrated compara-
ble sensitivity and speciﬁcity with CT scans in the detection
of endoleak following EVAR.27,28 To date, the main limita-
tion to its widespread use remains the experience of the
operator.
Finally, cost issues also play an important role when
discussing the use of stent grafts in young patients. EVAR 18
found that the average cost of aneurysm-related
Table 2. Randomized controlled trials comparing endovascular aortic aneurysm repair (EVAR) with open surgical repair (OSR) for
abdominal aortic aneurysms (AAA).
References Patients (n). Age
(mean  SD) (y)
Follow
up (y)
Peri-operative
mortality
Outcomes
EVAR 1, 2005,3 20108 539 with OSR 74  6.1 6 OSR: 6.2% Overall aneurysm related death: 1.2/100/year
with OSR vs. 1/100/year with EVAR (p ¼ .73)
Overall mortality: 7.1/100/year with OSR vs. 7.2/
100/year with EVAR (p ¼ .61)
Re-intervention rate: 1.7/100/year with OSR vs.
5.1/100/year with EVAR (p < .001)
No AAA rupture after OSR and 25 after EVAR
(4.6%)
543 with EVAR 74.2  6.0 EVAR: 2.1%
(p ¼ .001)
DREAM, 2005,4 20107 174 with OSR 69.6  6.8 6.4 OSR: 4.6% Overall mortality: 30.1% with OSR vs. 31.1% with
EVAR (NS)
AAA-related mortality: 4.49% with OSR vs. 1.15%
with EVAR (p < .001)
Re-intervention rate: 18.1% after OSR vs. 29.6%
after EVAR (p ¼ .003)
171 with EVAR 70.7  6.6 EVAR: 1.2%
(p ¼ .01)
OVER, 2009,2 20126 437 with OSR 70.5  7.8 5.2 OSR: 3% (p ¼ .004) Overall mortality: 33.4% after OSR vs. 32.9% after
EVAR (NS)
AAA-related mortality: 3.7% after OSR vs. 2.3%
after EVAR (NS)
AAA rupture: 0 after OR vs. 6 (1.4%) after EVAR
(p ¼ .03)
Re-intervention rate: 17.8% after OSR vs. 22.1%
after EVAR (NS)
444 with EVAR 69.6  7.8 EVAR: 0.5%
ACE, 201112 149 with OSR 70  7.1 3 OSR: 0.6% Overall mortality: 8% after OSR vs. 11.3% after
EVAR (NS)
AAA-related mortality: 0.6% after OSR vs. 4%
after EVAR (NS)
AAA rupture: 0 after OSR vs. 3 (2.0%) after EVAR
(NS)
Re-intervention rate: 2.7% after OSR vs. 16%
after EVAR (p < .0001)
150 with EVAR 68.9  7.7 EVAR: 1.3%
(p > .05, NS)
Note. NS ¼ not signiﬁcant.
620 F. Schneider and J.-B. Riccoprocedures after 8 years of follow-up was higher for EVAR
($23,153) than for OSR ($18,586). This raw analysis could be
unfair, as the costs of some laparotomy-related complica-
tions were not taken into account in the cost analysis.
However, even in recent series, EVAR continues to cost
more than OSR29 and an updated report from the French
Health Agency designed to evaluate the cost-effectiveness
of EVAR in France concluded that EVAR was not a viable
economic solution, especially in patients ﬁt for surgery.30CONCLUSION
There is no evidence in the recent literature to support
EVAR as the ﬁrst-line therapy in patients younger than 60
years. Open repair remains the best option for the majority
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